Schrader, Adrian
Netzer, Nils
Hielscher, Thomas
Görtz, Magdalena
Zhang, Kevin Sun
Schütz, Viktoria
Stenzinger, Albrecht
Hohenfellner, Markus
Schlemmer, Heinz-Peter
Bonekamp, David http://orcid.org/0000-0002-4811-0087
Funding for this research was provided by:
Bundesministerium für Wirtschaft und Klimaschutz (01MT21004B)
Article History
Received: 18 December 2023
Revised: 15 April 2024
Accepted: 21 April 2024
First Online: 2 July 2024
Compliance with ethical standards
:
: The scientific guarantor of this publication is David Bonekamp.
: Albrecht Stenzinger reports speakers honoraria for Aignostics, Amgen, Astra Zeneca, AGCT, Bayer, Bristol-Myers Squibb, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Qlucore, Pfizer, Roche, Seagen, Seattle Genetics, Takeda, Thermo Fisher and grants from Bayer, Bristol-Myers Squibb, Chugai, and Incyte. Heinz-Peter Schlemmer declares consulting fees or honoraria from Bayer, Bracco; travel support from Siemens, Bayer, Bracco; consultancy for Bayer; grants/grants pending from EU, BMBF, Deutsche Krebshilfe; payment for lectures from Bayer, Bracco. Heinz-Peter Schlemmer is member of the Advisory Editorial Board of European Radiology. He has not taken part in the review or selection process of this article. David Bonekamp received lecture payments from Bayer Vital. Heinz-Peter Schlemmer is a member of the European Radiology Editorial Board. He has not taken part in the review or selection process of this article. The remaining authors declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Thomas Hielscher, a co-author of this study, is a biostatistician at the German Cancer Research Center (DKFZ), Heidelberg, Germany, and contributed to the statistical analysis for this paper.
: Written informed consent was waived by the Institutional Review Board (S-164/2019) in Heidelberg.
: Institutional Review Board approval was obtained with ethics review in Heidelberg (S-164/2019).
: One thousand six hundred ten out of the 1627 MRI examinations included in this study have been previously reported. The previous publications focused on DL and radiomics [, , ], however, data have not been used for systematic clinical RC assessment or development. Regarding the PI-RADS/PSAD biopsy strategy, the test set of a previous study overlaps with 101 exams from biopsy-naïve patients with PI-RADS 3 lesions in the current study [].
: